Related Experiment Videos
[Clinical characteristics of velcade cumulative effect in resistant and recurrent multiple myeloma]
Aim:
To assess efficacy of velcade monotherapy in patients with resistent and recurrent multiple myeloma (MM).
Material And Methods:
Velcade was given to 29 patients (11 males and 18 females at the age 41-73 years) with resistant and recurrent MM of stage 3. A standard scheme was used - 1.3 mg/m2 iv jet on day 1, 4, 8 and 11. The cycle was 21 days, a total of 6 cycles. All the patients were examined immunochemically for serum and urine PIg. An antitumor effect was studied.
Results:
After, on the average, 3 courses of velcade therapy PIg reduction was 31.3%. The response was complete (CR) in 3.4%, partial (PR) in 44.6%, minor response (MR) in 17% and no response (NR) in 35% patients. After 6 cycles of velcade monotherapy given to 23 patients PIg reduction was 59%. CR, PR, MR, NR were seen in 2 (8.7%), 11 (47.8%), 4 (17.4%), 6(26.1%) patients, respectively. Progression occurred in 8.7%. After 3 cycles of velcade therapy in 29 patients an objective response occurred in 48%, after 6 cycles it increased to 56.5%. The group with poor respose (MR+NR) reduced from 52 (after 3 cycles) to 43.5% (after 6 cycles) patients. Cumulative toxicity of velcade 10 days after the end of cycles 3 and 6 was absent.
Related Concept Videos
Treatment Resistent Cancers
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Treatment Resistant Cancers
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Cytotoxic Edema: Pathophysiology
Therapeutic Drug Monitoring: Affecting Factors